. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):202–208. doi: 10.1097/QAI.0000000000001658

Table 4.

NC-AE medication use as a predictor for HIV treatment outcomes

Outcome	NC-AE medication use	Outcome/visits	(%)	OR (95% CI)	p-value
Reported cART use	No	12441/17375	(71.6)	1.46 (1.35–1.57)	<0.0001
Reported cART use	Yes	9731/12422	(78.3)	1.46 (1.35–1.57)	<0.0001

Reported adherence ≥95%^*	No	9210/11185	(82.3)	1.03 (0.95–1.12)	0.45
Reported adherence ≥95%^*	Yes	9072/10947	(82.9)	1.03 (0.95–1.12)	0.45

Undetectable viral load^§	No	8753/15998	(54.7)	1.12 (1.05–1.19)	0.0008
Undetectable viral load^§	Yes	6277/11350	(55.3)	1.12 (1.05–1.19)	0.0008

NC-AE medication use was used as the independent (predictor) variable for this analysis. Logistic regression analysis with exchangeable within-woman correlation was performed on all observations (visits) for all HIV-infected individuals. No NC-AE medication use was used as the reference.

= reported adherence to cART therapy in six months preceding visit.

^§

= both cART and non-CART visits included in the analysis.

OR= odds ratio. CI= confidence interval. cART= combination antiretroviral therapy.